Navigation Links
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Date:3/17/2008

eutical Development, and Chief Medical Officer. "Our approach mirrors our strategy for Genasense in melanoma in which a smaller Phase 3 trial, expected to complete accrual later this year, seeks to confirm efficacy by focusing on patients who derived maximum benefit in a large randomized trial. In parallel with collection and analysis of existing data in CLL, Genta has developed a new clinical trial, and the Company will file its draft protocol seeking formal Scientific Advice at the May meeting of the European Medicines Agency (EMEA). Genta greatly appreciates the professional and collaborative communications with FDA during this process, and we look forward to working closely with FDA in addressing their recommended options for securing the confirmatory data."

Proposed Confirmatory Trial of Genasense in CLL

The proposed protocol, based on results obtained during the previous trial, is a randomized controlled trial at first or second relapse in patients who are "non-refractory". All patients will receive fludarabine plus cyclophosphamide (Flu/Cy) - an accepted standard of care - and they will be randomly assigned to receive Genasense or no additional therapy. The trial will seek to confirm that the addition of Genasense increases complete responses (CR) in patients who receive Flu/Cy chemotherapy.

In the preceding Phase 3 trial, 241 patients with relapsed or refractory CLL were randomly assigned to receive Flu/Cy with or without Genasense. This study achieved its primary endpoint - an increase in the proportion of patients who achieved CR (17% vs. 7%; P=0.025). By definition, CR represents the complete elimination of all clinical signs of leukemia, combined with the elimination of leukemia-related symptoms. The duration of CR was also significantly longer for patients treated with Genasense (i.e., median not yet reached but exceeding 36 months in the Genasense group compared with 22 months for the Flu/Cy-only group).

In patients predefin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
2. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
3. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
11. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
(Date:4/24/2014)... 2014 ,Take me out to the ballgame, doesn,t ... chips. The more likely culprits include French fries, soda ... for children who play youth baseball, eating unhealthy food ... problems, according to researchers at Wake Forest Baptist Medical ... of Childhood Obesity , found that high-calorie snacks ...
(Date:4/24/2014)... long thought to be boring and irrelevant, could offer ... disease. , Researcher Dr Milena Furtado, and her team ... University, found the heart cell fibroblast is a close ... healthy beating heart. , In research published today in ... cardiac fibroblasts are unique cells due to their genetic ...
(Date:4/24/2014)... CHAMPAIGN, Ill. It is better to give than to ... enjoy giving, a new study suggests. , The study found ... such as giving their money to family members, are less ... thrill from taking risks or keeping the money for themselves. ... of the National Academy of Sciences . , The study ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
(Date:4/23/2014)... stool from healthy, unrelated donors was safe and ... caused by Clostridium difficile , according to ... Infectious Diseases and available online. Known as ... whether given via a colonoscope or a nasogastric ... this promising treatment more readily available to patients. ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
... 2008) The American Heart Associations Los Angeles Division ... of the paramedic model in use around the country ... Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). ... Heart Awards to Dr. Criley and William Koenig, Los ...
... April 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ... services, today announced that it entered into a ... security agreement with Sovereign,Business Capital ("SBC", formerly Business ... the loan credit facility, SBC takes,assignment of TeamStaff,s ...
... WEST BEND, Wis., April 3, 2008 Mach ... that the,final tests prior to large scale manufacturing ... week., "A highly qualified scientist from BioQual ... facility completing a technology transfer and,memorializing the protocols ...
... Earns Vesicare Gold Standard Status Over, Sales-Leading Detrol LA/Detrusitol ... ... Decision Resources, WALTHAM, Mass., April 3, 2008 Decision Resources, ... healthcare issues, finds that a drug,s effect on the,reduction of urge ...
... gases, radiation and pesticides as probable causes , , THURSDAY, ... the risk of miscarriage, apparently the result of being ... line of work, a new study found. , Not ... the risks, but veterinary offices and labs need to ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... company that develops, manufactures and markets advanced,in-vitro ... tumor,therapy systems, today announced the completion of ... (the "Kit"), a prostate cancer-specific,molecular diagnostic test ...
Cached Medicine News:Health News:Pioneer of paramedic model to be honored 2Health News:Pioneer of paramedic model to be honored 3Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Mach One Corporation Announces Completion of Final Tests Prior to Full Scale Production 2Health News:Astellas/GlaxoSmithKline's Vesicare Has Advantages Over Pfizer's Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence 2Health News:Women Veterinarians Face Higher Miscarriage Risk 2Health News:Women Veterinarians Face Higher Miscarriage Risk 3Health News:China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent 2
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
... These revised charts incorporate the slight change ... the 10 Sloan letters derived from the ... eyes during the ETDRS study. The original ... examination of 234 eyes. In addition to ...
... to diagnose Stereo and Binocular vision in children ... glasses. The test can be used for testing ... and depth perception. The Stereo Cube tests for ... arc and is ideal for optometric examinations as ...
... "natural" Stereotest consists of three test plates(6mm, 3mm, ... in a range of 600 - 15 seconds. ... can only be detected if stereopsis is present. ... risk of the patient learning the correct answer. ...
Medicine Products: